Pharma Stocks Plunge on Trump Tariff Threat

By By Rediff Money Desk, New Delhi
Apr 04, 2025 12:03
Pharmaceutical stocks tumbled up to 10% after reports of Trump imposing tariffs on imports. Aurobindo, Laurus, Ipca, Lupin, Biocon, and Cipla were among the hardest hit.
New Delhi, Apr 4 (PTI) Shares of Pharmaceutical companies on Friday tumbled up to 10 per cent amid reports that the Trump Administration will soon announce tariffs on pharma imports and emphasised that the measures will be "unprecedented".

According to reports, President Trump has said that tariffs on pharmaceuticals and semiconductors will be announced shortly, emphasising that the measures on pharmaceutical imports will be unprecedented.

The US has announced 26 per cent reciprocal tariffs on India saying New Delhi imposes high import duties on American goods.

Reacting to the reports the stock of Aurobindo Pharma plunged 11 per cent to Rs 1,049.85 apiece on the, Laurus Labs tumbled 9.5 per cent to Rs 561.55, Ipca labs decreased 9.3 per cent to Rs 1,357.80, Lupin dipped 8.41 per cent to Rs 1,918.20, Biocon 7.03 per cent to Rs 321.25, and Cipla declined 7 per cent to Rs 1,390.35.

In addition, Marksans Pharma's shares depreciated 6.7 per cent to Rs 217.40 per piece, Dr Reddys Laboratories declined 6.5 per cent to Rs 1,076.40 -- also its 52-week low -- Shilpa Medicare fell 6.4 per cent to Rs 633, and Sun Pharmaceutical Industries slipped 6.33 per cent to Rs 1,658.

Also, the scrip of Gland Pharma dipped 6 per cent to Rs 1,468.25 per share, Ajanta Pharma fell 5.4 per cent to Rs 2,480.05, Wockhardt depreciated by 5 per cent to hit a lower circuit band of Rs 1,347.55 on the exchange.

In Morning trade on Friday, the BSE healthcare index declined 1,347.88 points or 3.22 per cent to 40,522.91, while the 30-share BSE Sensex slumped 680.18 points or 0.89 per cent to 75,615.18.

Earlier, the Trump administration had exempted pharmaceuticals and semiconductors from the reciprocal tariff policy. Accordingly, shares of Pharmaceutical companies on Thursday had settled with gains of as much as 7 per cent.
Source: PTI
Read More On:
aurobindo pharmapharma stockslaurus labspharmaceutical importstrump tariffs
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

India's First Green Cargo Vessel Delivered to...

Udupi Cochin Shipyard delivers India's first eco-friendly cargo vessel to Norway,...

Tamilnad Mercantile Bank Q4 Net Profit Rises to...

Tamilnad Mercantile Bank reported a net profit of Rs 291.90 crore for Q4 FY25, driven...

Bajaj Housing Finance Q4 Profit Surges 54% to...

Bajaj Housing Finance's net profit jumped 54% to Rs 587 crore in Q4 FY25, driven by...

Karnataka Minister Discusses US Tariff Impact...

Karnataka Minister M B Patil holds meeting to assess the impact of US tariffs on key...

Rallis India Reports Rs 32 Cr Loss in Q4

Rallis India, a subsidiary of Tata Chemicals, reported a loss of Rs 32 crore in Q4...

Wendt (India) Ltd Q4 Profit: Rs 12.89 cr

Wendt (India) Ltd reported a consolidated net profit of Rs 12.89 crore for Q4 FY25,...

Tamil Nadu's Electronics Exports Hit Record...

Tamil Nadu achieved a record USD 14.65 billion in electronics exports for FY25,...

Ciklum Expands AI Presence in India with New Hubs

Ciklum doubles down on India's AI talent pool, opening new hubs in Chennai and Pune....

AI Health Insurance Advisor | Future Generali

Future Generali launches AI-powered health insurance advisor to help individuals...

Choice International Reports Strong Q4 Profit:...

Choice International reported a 36% jump in net profit to Rs 53 crore in Q4, driven by...

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2025 Rediff.com